

1. Record Nr.	UNISA996205350603316
Titolo	Viral hepatitis [[electronic resource] /] / edited by Howard Thomas, Stanley Lemon, Arie Zuckerman
Pubbl/distr/stampa	Malden, Mass., : Blackwell Pub., c2005 Hyattsville, MD : , : U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, , [2010]
ISBN	1-280-19731-5 9781405143886 9786610197316 0-470-76222-5 0-470-98713-8 1-4051-4388-6
Edizione	[3rd ed.]
Descrizione fisica	1 online resource (914 p.)
Collana	NCHS data brief, , 1941-4935 ; ; no. 27 DHHS Publication ; ; no. (PHS) 2010-1209
Altri autori (Persone)	ThomasH. C (Howard C.) LemonStanley M ZuckermanArie J
Disciplina	616.3 616.3/623 616.3623
Soggetti	Hepatitis, Viral Hepatitis B Hepatitis C Liver - Diseases Statistics.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Viral Hepatitis; Contents; Preface to the Third Edition; Contributors; Section I Introduction to Liver Biology; Chapter 1 Liver stem cells in persistent viral infection, liver regeneration and cancer; Chapter 2 Hepatic immunology; Section II Clinical Aspects of Viral Hepatitis; Chapter 3 Clinical features of hepatitis; Chapter 4 Diagnostic approach

to viral hepatitis; Chapter 5 Evolution of hepatitis viruses; Section III Hepatitis A Virus; Chapter 6 Structure and molecular virology; Chapter 7 Epidemiology; Chapter 8 Natural history and experimental models; Chapter 9 Prevention

Section IV Hepatitis B Virus and Other Hepadnaviridae Chapter 10 Structure and molecular virology; Chapter 11 Epidemiology; Chapter 12 Avihepadnaviridae; Chapter 13 Woodchuck hepatitis virus; Chapter 14 Hepatitis B surface antigen (HBsAg) variants; Chapter 15 Molecular variations in the core promoter, precore and core regions of hepatitis B virus, and their clinical signi. cance; Chapter 16 Natural history of chronic hepatitis B and hepatocellular carcinoma; Chapter 17 Hepatocellular carcinoma: molecular aspects in hepatitis B; Chapter 18 Murine models and hepatitis B virus infection

Chapter 19 Pathogenesis of chronic hepatitis B Chapter 20 Treatment of chronic hepatitis B; Chapter 21 Management of drug-resistant mutants; Chapter 22 Liver transplantation in the management of chronic viral hepatitis; Chapter 23 Prevention; Section V Hepatitis C Virus; Chapter 24 Structure and molecular virology; Chapter 25 Epidemiology; Chapter 26 The immune response to hepatitis C virus in acute and chronic infection; Chapter 27 Natural history and experimental models; Chapter 28 Autoimmune disorders; Chapter 29 Central nervous system complications; Chapter 30 In vitro replication models

Chapter 31 Progression of . brosis Chapter 32 The natural history of hepatitis C and hepatocellular carcinoma; Chapter 33 Treatment of chronic hepatitis C; Chapter 34 New drugs for the management of hepatitis C; Chapter 35 Prevention; Section VI Hepatitis D Virus; Chapter 36 Structure and molecular virology; Chapter 37 Epidemiology and natural history; Chapter 38 Treatment; Section VII Hepatitis E Virus; Chapter 39 Structure and molecular virology; Chapter 40 Hepatitis E as a zoonotic disease; Chapter 41 Epidemiology, clinical and pathologic features, diagnosis, and experimental models

Chapter 42 Prevention Section VIII Clinical Aspects of Viral Liver Disease; Chapter 43 Aetiology of fulminant hepatitis; Chapter 44 Treatment of fulminant hepatitis; Chapter 45 Hepatitis and haemophilia; Chapter 46 Occupational aspects of hepatitis; Chapter 47 Neonatal and paediatric infection; Chapter 48 Management of hepatocellular cancer; Chapter 49 Application of molecular biology to the diagnosis of viral hepatitis; Chapter 50 Hepatitis in HIV-infected persons; Chapter 51 Treatment of extrahepatic diseases caused by hepatitis B and hepatitis C viruses

Chapter 52 The histologist's role in the diagnosis and management of chronic hepatitis B and C

Sommario/riassunto

There has been an explosion of both the incidence and medical knowledge of viral hepatitis over the last two decades. Not only is the incidence of infection and disease increasing, but new hepatitis viruses have been discovered, as well as the launch of new pharmaceutical products. Previously published by Churchill Livingstone, *Viral Hepatitis* by Zuckerman & Thomas was the first comprehensive book on hepatitis and is recognized as the standard reference text in this field. The new third edition, now published by Blackwell Publishing, addresses the recent advan

2. Record Nr.	UNINA9910828521503321
Autore	Krebsz Markus
Titolo	Securitisation and structured finance post credit crunch : a best practice deal lifecycle guide / / by Markus Krebsz
Pubbl/distr/stampa	Chichester, West Sussex, : Wiley, 2011
ISBN	1-119-97381-3 1-283-40514-8 9786613405142 1-119-97793-2
Edizione	[2nd ed.]
Descrizione fisica	1 online resource (477 p.)
Collana	The Wiley Finance Series ; ; v.586
Disciplina	332.6 332.632
Soggetti	Asset-backed financing Corporations - Finance
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Includes index.
Nota di bibliografia	Includes bibliographical references (p. [433]-434) and index.
Nota di contenuto	Securitization and Structured Finance Post Credit Crunch; Contents; Preface; Acknowledgments; 1 Introduction; 1.1 Setting the scene: About this book; 1.2 Diagrammatical overview of deal lifecycle stages; 1.3 Role-based roadmap to the book; PART I THE CREDIT CRISIS AND BEYOND; 2 Looking back: What went wrong?; 2.1 Overview; 2.2 Data, disclosure, and standardization; 2.3 Paper reports; 2.4 Electronic reports; 2.5 Data feeds; 2.6 Definitions; 2.7 Reporting standards; 2.8 Underwriting standards; 2.9 Due diligence; 2.10 Deal motives; 2.11 Arbitrage; 2.12 Rating shopping 2.13 Overreliance on credit ratings2.14 Models, assumptions, and black boxes; 2.15 Proprietary analysis; 2.16 Risk management and risk mitigants; 2.17 Senior management awareness; 2.18 Lack of drilldown capability and group-wide controls; 2.19 Mark to market, mark to model, and pricing of illiquid bonds; 2.20 Government salvage schemes: What's next?; 2.21 Re-REMICS: Private vs. public ratings; 2.22 Conclusion; 3 Looking ahead: What has happened since?; 3.1 Current initiatives: An overview; 4 Sound practice principles; 4.1 Data; 4.2 Definitions; 4.3 Standards; 4.4 Investor focused

4.5 Motivation and deal drivers4.6 Analysis; PART II DEAL LIFECYCLE; 5 Strategy and feasibility; 5.1 Strategic considerations; 5.2 Key signs for securitization; 5.3 Deal structure type; 5.4 Asset classes; 5.5 Private issuance, public issuance, or conduit financing; 5.6 Credit enhancement and pricing; 5.7 Asset readiness and feasibility studies; 5.8 Documentation review; 5.9 Target portfolio and deal economics; 5.10 Indicative rating agency and financial modeling; 5.11 Ratings models; 5.12 Rating methodologies; 6 Pre close; 6.1 Typical execution timing; 6.2 Execution resources 6.3 Transaction counterparties6.4 Transaction documents; 6.5 Deal configuration; 7 At close; 7.1 Deal documents, marketing, and roadshow; 7.2 Pre-sale report; 7.3 Deal pricing and close; 7.4 New-issuance reports; 8 Post close; 8.1 Servicing and reporting; 8.2 Deal performance measurement; 8.3 The performance analytics process; 8.4 Deal redemption; PART III TOOLBOX; 9 Understanding complex transactions; 9.1 Structure diagrams; 9.2 Analytical capabilities; 9.3 The risk of overreliance on ratings; 9.4 Analytical roadmap; 10 Data; 10.1 The "meaning" of data; 10.2 Static information 10.3 Dynamic data points10.4 Data providers; PART IV ANALYTICAL TOOLS; 11 Vendors; 12 ABSXchange; 12.1 Introduction; 12.2 Performance data; 12.3 Pool performance; 12.4 Portfolio monitoring; 12.5 Creating benchmark indexes; 12.6 Cash flow analytics; 12.7 Single-bond cash flow analysis; 12.8 Single cash flow projection results; 12.9 Advanced functionality; 13 Bloomberg; 14 CapitalTrack; 14.1 Changing the data model used for structured finance instrument administration; 14.2 The big fly in the ointment; 14.3 CapitalTrack-the new model; 15 Fitch Solutions; 15.1 Products and services 15.2 Research services

Sommario/riassunto

Structured bonds are often viewed as complex and opaque, and participants in the securitization and structured finance markets have traditionally had a narrow focus on a specific part of the securitization value chain. However, in the post credit crunch environment, the market is more regulated, standardized, transparent, and better structured with closer-aligned and more balanced incentives for all participants, more focus on investors and improved comprehension of these bond instruments. In order for the market to succeed, it is vital that all participants take a broader view and understand
